0001022079-21-000146.txt : 20211201
0001022079-21-000146.hdr.sgml : 20211201
20211201163423
ACCESSION NUMBER: 0001022079-21-000146
CONFORMED SUBMISSION TYPE: 4
PUBLIC DOCUMENT COUNT: 1
CONFORMED PERIOD OF REPORT: 20211129
FILED AS OF DATE: 20211201
DATE AS OF CHANGE: 20211201
REPORTING-OWNER:
OWNER DATA:
COMPANY CONFORMED NAME: Doherty Catherine T.
CENTRAL INDEX KEY: 0001520897
FILING VALUES:
FORM TYPE: 4
SEC ACT: 1934 Act
SEC FILE NUMBER: 001-12215
FILM NUMBER: 211463461
MAIL ADDRESS:
STREET 1: C/O QUEST DIAGNOSTICS
STREET 2: 500 PLAZA DRIVE
CITY: SECAUCUS
STATE: NJ
ZIP: 07094
ISSUER:
COMPANY DATA:
COMPANY CONFORMED NAME: QUEST DIAGNOSTICS INC
CENTRAL INDEX KEY: 0001022079
STANDARD INDUSTRIAL CLASSIFICATION: SERVICES-MEDICAL LABORATORIES [8071]
IRS NUMBER: 161387862
STATE OF INCORPORATION: DE
FISCAL YEAR END: 1231
BUSINESS ADDRESS:
STREET 1: 500 PLAZA DRIVE
CITY: SECAUCUS
STATE: NJ
ZIP: 07094
BUSINESS PHONE: 9735202700
MAIL ADDRESS:
STREET 1: 500 PLAZA DRIVE
CITY: SECAUCUS
STATE: NJ
ZIP: 07094
FORMER COMPANY:
FORMER CONFORMED NAME: CORNING CLINICAL LABORATORIES INC
DATE OF NAME CHANGE: 19960903
4
1
wf-form4_163839444899069.xml
FORM 4
X0306
4
2021-11-29
0
0001022079
QUEST DIAGNOSTICS INC
DGX
0001520897
Doherty Catherine T.
500 PLAZA DRIVE
SECAUCUS
NJ
07094
0
1
0
0
SVP, Group Exec. Clin. Fran.
Common Stock
2021-11-29
4
M
0
37565
95.795
A
106294
D
Common Stock
2021-11-29
4
S
0
300
153.383
D
105994
D
Common Stock
2021-11-29
4
S
0
3250
154.792
D
102744
D
Common Stock
2021-11-29
4
S
0
3532
155.774
D
99212
D
Common Stock
2021-11-29
4
S
0
15908
156.855
D
83304
D
Common Stock
2021-11-29
4
S
0
14575
157.533
D
68729
D
Common Stock
4136
I
401(k)/SDCP
Non-Qualifed Stock Option (right to buy)
95.795
2021-11-29
4
M
0
37565
95.795
D
2027-02-21
Common Stock
37565.0
0
D
This exercise and sales reported were effected pursuant to a Rule 10b5-1 sales plan adopted by the reporting person on October 29, 2021.
This transaction was executed in multiple trades at prices ranging from $153.21 to $153.49. The price reported above reflects the weighted average sale price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected.
This transaction was executed in multiple trades at prices ranging from $154.21 to $155.20. The price reported above reflects the weighted average sale price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected.
This transaction was executed in multiple trades at prices ranging from $155.26 to $156.17. The price reported above reflects the weighted average sale price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected.
This transaction was executed in multiple trades at prices ranging from $156.27 to $157.26. The price reported above reflects the weighted average sale price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected.
This transaction was executed in multiple trades at prices ranging from $157.27 to $158.22. The price reported above reflects the weighted average sale price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected.
These underlying shares were acquired on a periodic basis by the trustee of the Company's tax qualified Profit Sharing (401(k)) and/or Supplemental Deferred Compensation Plan. The information was obtained from the plan administrator as of a current date. The number of shares is based on the account balance of the Company stock fund under each Plan (which includes some money market instruments) divided by the market price of the Company's stock as of that date.
The options vested in three annual installments beginning with the first on February 21, 2018, the second on February 21, 2019 and the final on February 21, 2020.
/s/ William J. O'Shaughnessy, Jr., Attorney in Fact for Catherine T. Doherty
2021-12-01